Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours
(2023) In Advances in Therapy 40(10). p.4675-4688- Abstract
Introduction: People living with acromegaly and neuroendocrine tumours (NETs) may be treated with injectable somatostatin receptor ligands (SRLs), administered by either a caregiver or as self-injection via a proprietary or generic device. Injection device attributes that contribute to ease of use and storage, minimise preparation requirements, and reduce injection pain are associated with improved adherence and more favourable therapeutic outcomes. The aim of this study was to assess current opinion surrounding favourable SRL device attributes for people living with acromegaly and NETs as well as that of their caregivers. Methods: Participants (healthcare professionals [HCPs] and patients/non-HCP caregivers) from 11 countries were... (More)
Introduction: People living with acromegaly and neuroendocrine tumours (NETs) may be treated with injectable somatostatin receptor ligands (SRLs), administered by either a caregiver or as self-injection via a proprietary or generic device. Injection device attributes that contribute to ease of use and storage, minimise preparation requirements, and reduce injection pain are associated with improved adherence and more favourable therapeutic outcomes. The aim of this study was to assess current opinion surrounding favourable SRL device attributes for people living with acromegaly and NETs as well as that of their caregivers. Methods: Participants (healthcare professionals [HCPs] and patients/non-HCP caregivers) from 11 countries were invited to answer survey questions related to their demographic, experience, and preferences as they relate to the real-world use of injectable SRL devices. Questions were developed based on review of available literature and meetings with a Scientific Committee. Results: Device attributes preferred by the patient/non-HCP caregiver group (n = 211) included confidence that the correct drug amount is delivered (76%), quick administration with minimal pain/discomfort (68%), and device safety (needle-safety and low risk of contamination; 53%). Device attributes preferred by HCPs (n = 52) were quick administration with minimal pain/discomfort (69%), correct use is easy to learn, confidence in handling the device (63%), and confidence that the correct drug amount is delivered (62%). Conclusion: The results identified key features of injection devices for SRL therapy which merit consideration for optimal management and underscore the importance of patient partnership in treatment decisions.
(Less)
- author
- Jørgensen, Jens Otto Lunde ; de Herder, Wouter W. ; Martin, Wendy A. ; Kolarova, Teodora ; Marks, Muriël ; Follin, Cecilia LU ; Geilvoet, Wanda and Melmed, Shlomo
- organization
- publishing date
- 2023-10
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Acromegaly, NETs, Neuroendocrine tumours, Somatostatin receptor ligand, SRL
- in
- Advances in Therapy
- volume
- 40
- issue
- 10
- pages
- 14 pages
- publisher
- Springer
- external identifiers
-
- pmid:37573277
- scopus:85167778443
- ISSN
- 0741-238X
- DOI
- 10.1007/s12325-023-02627-6
- language
- English
- LU publication?
- yes
- id
- 07327e2e-14bd-4611-a45d-eedc4dbcf80d
- date added to LUP
- 2023-12-01 14:25:56
- date last changed
- 2024-04-14 14:46:44
@article{07327e2e-14bd-4611-a45d-eedc4dbcf80d,
abstract = {{<p>Introduction: People living with acromegaly and neuroendocrine tumours (NETs) may be treated with injectable somatostatin receptor ligands (SRLs), administered by either a caregiver or as self-injection via a proprietary or generic device. Injection device attributes that contribute to ease of use and storage, minimise preparation requirements, and reduce injection pain are associated with improved adherence and more favourable therapeutic outcomes. The aim of this study was to assess current opinion surrounding favourable SRL device attributes for people living with acromegaly and NETs as well as that of their caregivers. Methods: Participants (healthcare professionals [HCPs] and patients/non-HCP caregivers) from 11 countries were invited to answer survey questions related to their demographic, experience, and preferences as they relate to the real-world use of injectable SRL devices. Questions were developed based on review of available literature and meetings with a Scientific Committee. Results: Device attributes preferred by the patient/non-HCP caregiver group (n = 211) included confidence that the correct drug amount is delivered (76%), quick administration with minimal pain/discomfort (68%), and device safety (needle-safety and low risk of contamination; 53%). Device attributes preferred by HCPs (n = 52) were quick administration with minimal pain/discomfort (69%), correct use is easy to learn, confidence in handling the device (63%), and confidence that the correct drug amount is delivered (62%). Conclusion: The results identified key features of injection devices for SRL therapy which merit consideration for optimal management and underscore the importance of patient partnership in treatment decisions.</p>}},
author = {{Jørgensen, Jens Otto Lunde and de Herder, Wouter W. and Martin, Wendy A. and Kolarova, Teodora and Marks, Muriël and Follin, Cecilia and Geilvoet, Wanda and Melmed, Shlomo}},
issn = {{0741-238X}},
keywords = {{Acromegaly; NETs; Neuroendocrine tumours; Somatostatin receptor ligand; SRL}},
language = {{eng}},
number = {{10}},
pages = {{4675--4688}},
publisher = {{Springer}},
series = {{Advances in Therapy}},
title = {{Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours}},
url = {{http://dx.doi.org/10.1007/s12325-023-02627-6}},
doi = {{10.1007/s12325-023-02627-6}},
volume = {{40}},
year = {{2023}},
}